S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

$148.50
-3.59 (-2.36%)
(As of 04/12/2024 ET)
Today's Range
$148.28
$151.80
50-Day Range
$146.51
$172.18
52-Week Range
$143.52
$218.88
Volume
428,052 shs
Average Volume
538,883 shs
Market Capitalization
$18.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$216.12

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
45.5% Upside
$216.12 Price Target
Short Interest
Healthy
2.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.49mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.54) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

115th out of 923 stocks

Pharmaceutical Preparations Industry

43rd out of 431 stocks

ALNY stock logo

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

ALNY Stock News Headlines

Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Jefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
TD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/13/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$216.12
High Stock Price Target
$395.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+45.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
18 Analysts

Profitability

Net Income
$-440,240,000.00
Pretax Margin
-23.71%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Book Value
($1.76) per share

Miscellaneous

Free Float
124,183,000
Market Cap
$18.70 billion
Optionable
Optionable
Beta
0.39

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Yvonne L. Greenstreet M.B.A. (Age 61)
    MBChB, CEO & Director
    Comp: $2.09M
  • Mr. Jeffrey V. Poulton M.B.A.Mr. Jeffrey V. Poulton M.B.A. (Age 56)
    CFO & Executive VP
    Comp: $972.35k
  • Dr. Akshay K. Vaishnaw M.D. (Age 61)
    Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board
    Comp: $1.24M
  • Dr. Pushkal P. Garg M.D. (Age 56)
    Chief Medical Officer and Executive VP of Development & Medical Affairs
    Comp: $1M
  • Mr. Timothy J. Maines
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 55)
    Senior VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom (Age 43)
    Senior VP of Investor Relations & Corporate Communications
  • Mr. Piyush Sharma J.D.
    Chief Ethics & Compliance Officer
  • Mr. Evan Lippman
    Chief Corporate Development & Strategy Officer
  • Ms. Kelley Boucher
    Chief Human Resource Officer

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals has a diverse portfolio of marketed products, including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, targeting various rare diseases, which can provide a stable revenue stream.
  • The company has shown consistent revenue growth, with a 31.2% increase year-over-year, indicating a positive trajectory in its financial performance.
  • Recent earnings results have exceeded analyst expectations, with the company reporting a better-than-expected EPS, showcasing strong operational efficiency.
  • Institutional investors have been increasing their stakes in Alnylam Pharmaceuticals, signaling confidence in the company's future prospects and growth potential.
  • Alnylam Pharmaceuticals' focus on developing novel therapeutics based on ribonucleic acid interference demonstrates a commitment to cutting-edge technology and innovation in the biopharmaceutical industry.

Cons

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The stock of Alnylam Pharmaceuticals has a beta of 0.39, indicating lower volatility compared to the market, which may result in slower price movements for traders seeking higher returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 9, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price target for 2024?

18 brokerages have issued 12 month price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they predict the company's stock price to reach $216.12 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2024?

Alnylam Pharmaceuticals' stock was trading at $191.41 on January 1st, 2024. Since then, ALNY shares have decreased by 22.4% and is now trading at $148.50.
View the best growth stocks for 2024 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The biopharmaceutical company earned $439.72 million during the quarter, compared to analysts' expectations of $439.38 million. The company's revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.68) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include First Hawaiian Bank (0.00%) and Los Angeles Capital Management LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners